Skip to content

Non-invasive glycocalyx measurements in premature atherosclerosis

Non-invasive glycocalyx measurements in premature atherosclerosis - Non-invasive glycocalyx measurements in PA

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON33763
Enrollment
40
Registered
2009-04-01
Start date
2009-08-15
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis vascular abnormalities

Interventions

None listed

Sponsors

Universiteit Maastricht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Cases: - a cardiac, cerebral or peripheral vascular disease before the age of 40 - a positive family history for cardiovascular disease, defined as a first degree family member with a cardiovascular event before the age of 55 for men and 60 for women. Furthermore, they should be between the age of 36 and 56 years old. Controls: -Controls will be defined as healthy in case they have no cardiovascular history, such as no cardiac, cerebrovascular or peripheral artery disease and no complaints of angina, claudication or TIA and no family history for cardiovascular disease. Furthermore, they should be between the age of 36 and 56 years old.

Exclusion criteria

Exclusion criteria: Cases: - a positive history for hypertension or diabetes mellitus - pregnancy or lactating women - subjects below the age of 18 - unable to give informed consent Controls: Diseases mentioned at the inclusioncriteria.

Design outcomes

Primary

MeasureTime frame
Change in glycocalyx volume, before and after sublingual nitroglycerine administration between the different study groups

Secondary

MeasureTime frame
To compair the glycocalyx volume of the different study groups we measure this year, with last year's measurements.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)